Verrica Pharmaceuticals Inc.
VRCA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $14,344 | $12,702 | $3,439 | $344 |
| % Growth | 12.9% | 269.4% | 899.7% | – |
| Cost of Goods Sold | $1,109 | $340 | $423 | $625 |
| Gross Profit | $13,235 | $12,362 | $3,016 | -$281 |
| % Margin | 92.3% | 97.3% | 87.7% | -81.7% |
| R&D Expenses | $2,205 | $1,846 | $2,284 | $1,167 |
| G&A Expenses | $0 | $0 | $8,548 | $6,183 |
| SG&A Expenses | $9,403 | $8,852 | $8,848 | $9,878 |
| Sales & Mktg Exp. | $0 | $0 | $300 | $3,696 |
| Other Operating Expenses | $0 | $154 | $14 | $84 |
| Operating Expenses | $11,608 | $10,852 | $11,146 | $11,129 |
| Operating Income | $1,627 | $1,510 | -$8,130 | -$11,410 |
| % Margin | 11.3% | 11.9% | -236.4% | -3,316.9% |
| Other Income/Exp. Net | -$1,901 | -$1,306 | -$1,612 | -$4,792 |
| Pre-Tax Income | -$274 | $204 | -$9,742 | -$16,202 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$274 | $204 | -$9,742 | -$16,202 |
| % Margin | -1.9% | 1.6% | -283.3% | -4,709.9% |
| EPS | -0.03 | 0.022 | -1.03 | -2.41 |
| % Growth | -239.5% | 102.1% | 57.3% | – |
| EPS Diluted | -0.03 | 0.022 | -1.03 | -2.41 |
| Weighted Avg Shares Out | 9,490 | 9,488 | 9,484 | 6,733 |
| Weighted Avg Shares Out Dil | 9,490 | 9,491 | 9,484 | 6,733 |
| Supplemental Information | – | – | – | – |
| Interest Income | $159 | $228 | $337 | $205 |
| Interest Expense | $2,094 | $2,131 | $2,203 | $2,349 |
| Depreciation & Amortization | $184 | $199 | $208 | $253 |
| EBITDA | $2,004 | $2,534 | -$7,331 | -$13,600 |
| % Margin | 14% | 19.9% | -213.2% | -3,953.5% |